Literature DB >> 7827133

The reaction of methylglyoxal with human and bovine lens proteins.

M L Riley1, J J Harding.   

Abstract

Methylglyoxal is an endogenous metabolite that increases in diabetes and has been implicated in some of its long-term complications such as retinopathy, neuropathy and cataract. We investigated the reaction of methylglyoxal with isolated human and bovine lens crystallins (alpha, beta H, beta L and gamma). After 7 days incubation at 37 degrees C and pH 6.9, the reaction of methylglyoxal with lens proteins yielded stable adducts that exhibited fluorescent properties. SDS-polyacrylamide gel electrophoresis was used to monitor aggregation and crosslinking of the modified protein and autoradiography showed that [14C]methylglyoxal was incorporated into all the protein bands. Bovine gamma-crystallin was the most reactive towards methylglyoxal. Reaction of methylglyoxal with bovine gamma II-crystallin, which is found mainly in the lens nucleus, could alter the change surface network of the molecule, resulting in aggregation, increased light scattering and hence cataract. Modification of gamma II-crystallin by methylglyoxal produced an overall loss of positive charge and an increase in molecular weight and non-disulfide covalent crosslinking. Amino acid analysis of the modified gamma II-crystallin showed a loss of 47% of arginine residues.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7827133     DOI: 10.1016/0925-4439(94)00069-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

1.  Argpyrimidine, a methylglyoxal-derived advanced glycation end-product in familial amyloidotic polyneuropathy.

Authors:  Ricardo Gomes; Marta Sousa Silva; Alexandre Quintas; Carlos Cordeiro; António Freire; Paulino Pereira; Américo Martins; Estela Monteiro; Eduardo Barroso; Ana Ponces Freire
Journal:  Biochem J       Date:  2005-01-15       Impact factor: 3.857

2.  Advanced glycation end products in human senile and diabetic cataractous lenses.

Authors:  S Zarina; H R Zhao; E C Abraham
Journal:  Mol Cell Biochem       Date:  2000-07       Impact factor: 3.396

3.  Effects of modifications of alpha-crystallin on its chaperone and other properties.

Authors:  Barry K Derham; John J Harding
Journal:  Biochem J       Date:  2002-06-15       Impact factor: 3.857

4.  In vivo acetylation identified at lysine 70 of human lens alphaA-crystallin.

Authors:  P P Lin; R C Barry; D L Smith; J B Smith
Journal:  Protein Sci       Date:  1998-06       Impact factor: 6.725

5.  Chemical Reactivity and Respiratory Toxicity of the α-Diketone Flavoring Agents: 2,3-Butanedione, 2,3-Pentanedione, and 2,3-Hexanedione.

Authors:  Daniel L Morgan; Micheal P Jokinen; Crystal L Johnson; Herman C Price; William M Gwinn; Ronald W Bousquet; Gordon P Flake
Journal:  Toxicol Pathol       Date:  2016-03-29       Impact factor: 1.902

6.  Effect of dicarbonyl-induced browning on alpha-crystallin chaperone-like activity: physiological significance and caveats of in vitro aggregation assays.

Authors:  M Satish Kumar; P Yadagiri Reddy; P Anil Kumar; Ira Surolia; G Bhanuprakash Reddy
Journal:  Biochem J       Date:  2004-04-15       Impact factor: 3.857

7.  Novel quercetin derivatives in treatment of peroxynitrite-oxidized SERCA1.

Authors:  Petronela Žižková; Dušan Blaškovič; Magdaléna Májeková; L'ubomír Švorc; Lucia Račková; L'ubica Ratkovská; Miroslav Veverka; L'ubica Horáková
Journal:  Mol Cell Biochem       Date:  2013-10-19       Impact factor: 3.396

8.  Neo-Epitopes Generated on Hydroxyl Radical Modified GlycatedIgG Have Role in Immunopathology of Diabetes Type 2.

Authors:  Sidra Islam; Abdul Rouf Mir; Alok Raghav; Farzana Khan; Khursheed Alam; Asif Ali; Moin Uddin
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

9.  Substrate Protein Interactions and Methylglyoxal Modifications Reduce the Aggregation Propensity of Human Alpha-A-Crystallin G98R Mutant.

Authors:  Puttur Santhoshkumar; Krishna K Sharma
Journal:  Front Mol Biosci       Date:  2022-04-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.